Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
217 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-07-31
Study Completion Date
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Endovascular treatment of acute ischemic stroke has shown strong benefit in several prospective randomized trials in the anterior circulation and endovascular therapy for basilar artery occlusion has shown promising results in several single-arm studies. This has led to a broad adoption of these techniques which are now considered standard of care in many institutions despite the lack of adequate evidence to prove their benefit. Indeed, the rates of symptomatic intracerebral hemorrhage in these studies have consistently been around 5% which raises the question as to whether patients could actually be harmed as opposed to helped by these procedures. This is a prospective, multi-center, randomized, controlled, open, blinded-endpoint trial, with the aim to evaluate the hypothesis that mechanical embolectomy with the Solitaire device is superior to medical management alone in achieving better outcomes in subjects presenting with an acute ischemic stroke caused by occlusion of the basilar artery within 6-24 hours from symptom onset.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Basilar Artery Occlusion Chinese Endovascular Trial in the Extended Time Window
NCT06560203
Acute Ischemic Stroke
Basilar Artery Occlusion
RECRUITING
NA
Endovascular Treatment for Acute Basilar Artery Occlusion
NCT04751708
Basilar Artery Occlusion
Acute Cerebrovascular Accident
Stroke Due to Basilar Artery Occlusion
COMPLETED
NA
Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion
NCT05827042
Basilar Artery Occlusion
Acute Cerebrovascular Accident
Stroke Due to Basilar Artery Occlusion
RECRUITING
PHASE3
Basilar Artery Occlusion Chinese Endovascular Registry in Patients With Large-Core Infarct
NCT07345702
Basilar Artery Occlusion
Ischemic Stroke
Large Core Infarct
NOT_YET_RECRUITING
Endovascular Treatment for Mild Stroke With Acute Anterior Circulation Large Vessel Occlusion
NCT06179017
Endovascular Treatment
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Objective: To evaluate the hypothesis that mechanical embolectomy with the Solitaire device is superior to medical management alone in achieving favourable outcomes defined as modified Rankin score (mRS) 0-3 at 90 days in subjects presenting with ischemic stroke due to basilar artery occlusion up to 24 hours from symptom onset.
Subject Population: Subjects presenting with acute ischemic stroke within 6-24 hours from symptom onset/last seen well and whose strokes are attributable to an occlusion of the basilar artery. Subjects are either ineligible for IV alteplase or have received IV alteplase therapy without recanalization. The randomization employs a 1:1 ratio of mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration versus medical management alone. Randomization will be done under a stratification process using age, baseline National Institute of Health Stroke Scale (NIHSS) and therapeutic window. For the primary endpoint, subjects will be followed for 90 days post-randomization.Sample size is projected to be 318 patients.
Care providers: Vascular neurologists and trained interventional neuroradiologists or neurologists in certified comprehensive stroke centers that treat more than 500 acute stroke patients and perform more than 30 acute mechanical thrombectomies every year will treat patients. Neurointerventionalists have to have previously performed at least 10 thrombectomies with Solitaire device in acute ischemic stroke patients.
Interventions: Patients in both arms will be admitted at acute stroke units (or Intensive Care Unit if needed) and treated following the Chinese Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Concomitant medications and non-pharmacological therapies will be recorded. If a decision of stopping support life measures is adopted, this will be recorded in the Case Report Form (CRF).A maximum of six attempts to retrieve the thrombus in a single vessel can be made with any Solitaire device or aspiration. In case an atherosclerotic lesion is found underlying the occlusive lesion angioplasty/stenting through detachment of the Solitaire device will be allowed.
Subject Population: Subjects presenting with acute ischemic stroke within 6-24 hours from symptom onset/last seen well and whose strokes are attributable to an occlusion of the basilar artery. Subjects are either ineligible for IV alteplase or have received IV alteplase therapy without recanalization. The randomization employs a 1:1 ratio of mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration versus medical management alone. Randomization will be done under a stratification process using age, baseline National Institute of Health Stroke Scale (NIHSS) and therapeutic window. For the primary endpoint, subjects will be followed for 90 days post-randomization.Sample size is projected to be 318 patients.
Care providers: Vascular neurologists and trained interventional neuroradiologists or neurologists in certified comprehensive stroke centers that treat more than 500 acute stroke patients and perform more than 30 acute mechanical thrombectomies every year will treat patients. Neurointerventionalists have to have previously performed at least 10 thrombectomies with Solitaire device in acute ischemic stroke patients.
Interventions: Patients in both arms will be admitted at acute stroke units (or Intensive Care Unit if needed) and treated following the Chinese Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Concomitant medications and non-pharmacological therapies will be recorded. If a decision of stopping support life measures is adopted, this will be recorded in the Case Report Form (CRF).A maximum of six attempts to retrieve the thrombus in a single vessel can be made with any Solitaire device or aspiration. In case an atherosclerotic lesion is found underlying the occlusive lesion angioplasty/stenting through detachment of the Solitaire device will be allowed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Basilar Artery Occlusion
Ischemic Stroke
Cerebrovascular Disorders
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endovascular Arm
Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
Best Medical Treatment and maximum supportive care
Group Type
EXPERIMENTAL
Mechanical embolectomy
Intervention Type
PROCEDURE
Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
Medical Treatment
Intervention Type
DRUG
Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
Control Arm
Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
Group Type
OTHER
Medical Treatment
Intervention Type
DRUG
Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mechanical embolectomy
Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
Intervention Type
PROCEDURE
Medical Treatment
Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Posterior circulation AIS within 6-24 hours from symptom onset/last seen well where patient is ineligible for i.v. thrombolytic treatment, or patient has received i.v. thrombolytic therapy without recanalization.
2. Occlusion (Thrombolysis in Myocardial Infarction, TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries as evidenced by computed tomography (CT) angiography, magnetic resonance (MR) angiography or angiogram.
3. Age ≥18 and ≤80 years.
4. Baseline National Institutes of Health Stroke Scale (NIHSS) score obtained prior to randomization must be equal to or higher than 6 points.
5. No significant pre-stroke functional disability (modified Rankin Scale, mRS ≤ 1).
6. Patient treatable within 24 hours from time last seen well. Isolated vertigo with nausea and/or vomiting is not considered onset of symptom.
7. Informed consent obtained from patient or acceptable patient surrogate.
2. Occlusion (Thrombolysis in Myocardial Infarction, TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries as evidenced by computed tomography (CT) angiography, magnetic resonance (MR) angiography or angiogram.
3. Age ≥18 and ≤80 years.
4. Baseline National Institutes of Health Stroke Scale (NIHSS) score obtained prior to randomization must be equal to or higher than 6 points.
5. No significant pre-stroke functional disability (modified Rankin Scale, mRS ≤ 1).
6. Patient treatable within 24 hours from time last seen well. Isolated vertigo with nausea and/or vomiting is not considered onset of symptom.
7. Informed consent obtained from patient or acceptable patient surrogate.
Exclusion Criteria
1. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with international normalized ratio \> 3.0.
2. Baseline platelet count \< 50.000/µL.
3. Baseline blood glucose \< 50mg/dL or \> 400mg/dL.
4. Severe, sustained hypertension (systolic blood pressure \> 220 mm Hg or diastolic blood pressure \> 110 mm Hg).
5. Patients in sedation and/or intubated patients could not be included if baseline NIHSS is not obtained by a neurologist or emergency physician prior to sedation or intubation.
6. Seizures at stroke onset which would preclude obtaining a baseline NIHSS.
7. Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.
8. History of life threatening allergy (more than rash) to contrast medium
9. Subjects who has received i.v. tissue plasminogen activator (t-PA) treatment beyond 4.5 hours from the beginning of the symptoms.
10. Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery (beyond 48h they should be randomized in BAOCHE or excluded for endovascular treatment if poor medical conditions).
11. Renal insufficiency with creatinine ≥ 3 mg/dl.
12. Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.
13. Subject participating in a study involving an investigational drug or device that would impact this study.
14. Cerebral vasculitis.
15. Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations; mRS score at baseline must be ≤ 1.
16. Unlikely to be available for 90 days follow-up.
1. Hypodensity amounting to a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) \< 6 and Pons-midbrain-index of ≥ 3 on CT angiography source images or MR with diffusion-weighted imaging or NCCT.
2. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).
3. Complete cerebellar infarct on CT or MRI with significant mass effect and compression of the fourth ventricle.
4. Complete unilateral or bilateral thalamic infarction on CT or MRI
5. Evidence of vertebral occlusion, high grade stenosis or arterial dissection in the extracranial or intracranial segment that cannot be treated or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels precluding device delivery/deployment.
6. Subjects with occlusions in both anterior and posterior circulation.
7. Evidence of intracranial tumor (except small meningioma).
2. Baseline platelet count \< 50.000/µL.
3. Baseline blood glucose \< 50mg/dL or \> 400mg/dL.
4. Severe, sustained hypertension (systolic blood pressure \> 220 mm Hg or diastolic blood pressure \> 110 mm Hg).
5. Patients in sedation and/or intubated patients could not be included if baseline NIHSS is not obtained by a neurologist or emergency physician prior to sedation or intubation.
6. Seizures at stroke onset which would preclude obtaining a baseline NIHSS.
7. Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.
8. History of life threatening allergy (more than rash) to contrast medium
9. Subjects who has received i.v. tissue plasminogen activator (t-PA) treatment beyond 4.5 hours from the beginning of the symptoms.
10. Patients with acute stroke within the first 48 hours after percutaneous cardiac, cerebrovascular interventions and major surgery (beyond 48h they should be randomized in BAOCHE or excluded for endovascular treatment if poor medical conditions).
11. Renal insufficiency with creatinine ≥ 3 mg/dl.
12. Woman of childbearing potential who is known to be pregnant or lactating or who has a positive pregnancy test on admission.
13. Subject participating in a study involving an investigational drug or device that would impact this study.
14. Cerebral vasculitis.
15. Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations; mRS score at baseline must be ≤ 1.
16. Unlikely to be available for 90 days follow-up.
1. Hypodensity amounting to a posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) \< 6 and Pons-midbrain-index of ≥ 3 on CT angiography source images or MR with diffusion-weighted imaging or NCCT.
2. CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed).
3. Complete cerebellar infarct on CT or MRI with significant mass effect and compression of the fourth ventricle.
4. Complete unilateral or bilateral thalamic infarction on CT or MRI
5. Evidence of vertebral occlusion, high grade stenosis or arterial dissection in the extracranial or intracranial segment that cannot be treated or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels precluding device delivery/deployment.
6. Subjects with occlusions in both anterior and posterior circulation.
7. Evidence of intracranial tumor (except small meningioma).
Minimum Eligible Age
18 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhangzhou Municipal Hospital of Fujian Province
OTHER
Sponsor Role
collaborator
The First People's Hospital of Changzhou
OTHER
Sponsor Role
collaborator
Xinqiao Hospital of Chongqing
OTHER
Sponsor Role
collaborator
Changhai Hospital
OTHER
Sponsor Role
collaborator
Baotou Central Hospital
OTHER
Sponsor Role
collaborator
904th Hospital of the Joint Logistics Support Force of the PLA
OTHER
Sponsor Role
collaborator
Linyi People's Hospital
OTHER
Sponsor Role
collaborator
The 985 Hospital of PLA, Taiyuan, Shanxi
UNKNOWN
Sponsor Role
collaborator
The First Affiliated Hospital with Nanjing Medical University
OTHER
Sponsor Role
collaborator
Tianjin TEDA Hospital
UNKNOWN
Sponsor Role
collaborator
Liaocheng People's Hospital
OTHER
Sponsor Role
collaborator
Luoyang Central Hospital
OTHER
Sponsor Role
collaborator
Subei People's Hospital of Jiangsu Province
OTHER
Sponsor Role
collaborator
PLA 148 Hospital, Zibo, Shandong
UNKNOWN
Sponsor Role
collaborator
Hebei General Hospital
OTHER
Sponsor Role
collaborator
Shengli Oilfield Hospital
OTHER
Sponsor Role
collaborator
Shenzhen Bao'an District People's Hospital
UNKNOWN
Sponsor Role
collaborator
The First Hospital of Jilin University
OTHER
Sponsor Role
collaborator
Henan Provincial People's Hospital
OTHER
Sponsor Role
collaborator
Peking University Binhai Hospital
UNKNOWN
Sponsor Role
collaborator
Beijing Tiantan Hospital
OTHER
Sponsor Role
collaborator
The Military General Hospital of Beijing, PLA
UNKNOWN
Sponsor Role
collaborator
The First Affiliated Hospital of Shanxi Medical University
OTHER
Sponsor Role
collaborator
Beijing Luhe Hospital
OTHER
Sponsor Role
collaborator
Affiliated Hospital of Nantong University
OTHER
Sponsor Role
collaborator
The Affiliated Hospital Of Guizhou Medical University
OTHER
Sponsor Role
collaborator
Nanning Second People's Hospital
OTHER
Sponsor Role
collaborator
Chongqing Three Gorges Central Hospital
OTHER
Sponsor Role
collaborator
The First Affiliated Hospital of Dalian Medical University
OTHER
Sponsor Role
collaborator
The Fifth Central Hospital of Tianjin，TianJin
UNKNOWN
Sponsor Role
collaborator
Yantaishan Hospital
UNKNOWN
Sponsor Role
collaborator
Nanyang Central Hospital
OTHER
Sponsor Role
collaborator
Second Affiliated Hospital of Soochow University
OTHER
Sponsor Role
collaborator
Tianjin Huanhu Hospital
OTHER
Sponsor Role
collaborator
The Affiliated Hospital of Northwest University, Xi'an NO.3 Hospital
UNKNOWN
Sponsor Role
collaborator
Xuanwu Hospital, Beijing
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xunming Ji, MD
Role: PRINCIPAL_INVESTIGATOR
Xuanwu Hospital, Beijing
Tudor G Jovin, MD
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburg Medical Center Stroke
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baotou Central Hospital
Baotou, , China
Site Status
Beijing Luhe Hospital
Beijing, , China
Site Status
Beijing Tiantan Hospital
Beijing, , China
Site Status
The Military General Hospital of Beijing, PLA
Beijing, , China
Site Status
Xuanwu Hospital
Beijing, , China
Site Status
The First People's Hospital of Changzhou
Changzhou, , China
Site Status
Chongqing Three Gorges Central Hospital
Chongqing, , China
Site Status
Xinqiao Hospital of Chongqing
Chongqing, , China
Site Status
Shengli Oilfield Hospital
Dongying, , China
Site Status
The Affiliated Hospital Of Guizhou Medical University
Guiyang, , China
Site Status
First Hospital of Jilin University
Jilin, , China
Site Status
Liaocheng Third People's Hospital
Liaocheng, , China
Site Status
Linyi People's Hospital
Linyi, , China
Site Status
Luoyang Central Hospital
Luoyang, , China
Site Status
Nanjing First People's Hospital
Nanjing, , China
Site Status
The First Affiliated Hospital with Nanjing Medical University
Nanjing, , China
Site Status
Nanning Second People's Hospital
Nanning, , China
Site Status
Nantong University
Nantong, , China
Site Status
Nanyang Central Hospital
Nanyang, , China
Site Status
Changhai Hospital
Shanghai, , China
Site Status
Shenzhen Bao'an District People's Hospital
Shenzhen, , China
Site Status
Hebei General Hospital
Shijiazhuang, , China
Site Status
Second Affiliated Hospital of Soochow University
Suzhou, , China
Site Status
PLA 264 Hospital
Taiyuan, , China
Site Status
The First Affiliated Hospital of Shanxi Medical University
Taiyuan, , China
Site Status
Peking University Binhai Hospital
Tianjin, , China
Site Status
The Fifth Central Hospital of Tianjin
Tianjin, , China
Site Status
Tianjin Huanhu Hospital
Tianjin, , China
Site Status
Tianjin TEDA Hospital
Tianjin, , China
Site Status
The 101st Hospital of Chinese People's Liberation Army
Wuxi, , China
Site Status
The Affiliated Hospital of Northwest University, Xi'an NO.3 Hospital
Xi'an, , China
Site Status
Subei People's Hospital of Jiangsu Province
Yangzhou, , China
Site Status
Yantaishan Hospital
Yantai, , China
Site Status
Zhangzhou Municipal Hospital of Fujian Province
Zhangzhou, , China
Site Status
Henan Provincial Hospital
Zhengzhou, , China
Site Status
PLA 148 Hospital
Zibo, , China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
References
Explore related publications, articles, or registry entries linked to this study.
Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O'Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014 Jan 18;383(9913):245-54. doi: 10.1016/s0140-6736(13)61953-4.
Reference Type
BACKGROUND
Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, Li Y, Wang L, Liu Y, Yin P, Liu J, Yu S, Tan F, Barber RM, Coates MM, Dicker D, Fraser M, Gonzalez-Medina D, Hamavid H, Hao Y, Hu G, Jiang G, Kan H, Lopez AD, Phillips MR, She J, Vos T, Wan X, Xu G, Yan LL, Yu C, Zhao Y, Zheng Y, Zou X, Naghavi M, Wang Y, Murray CJ, Yang G, Liang X. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016 Jan 16;387(10015):251-72. doi: 10.1016/S0140-6736(15)00551-6. Epub 2015 Oct 26.
Reference Type
BACKGROUND
Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, Wan X, Yu S, Jiang Y, Naghavi M, Vos T, Wang H, Lopez AD, Murray CJ. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013 Jun 8;381(9882):1987-2015. doi: 10.1016/S0140-6736(13)61097-1.
Reference Type
BACKGROUND
Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke. 2011 Dec;42(12):3651-4. doi: 10.1161/STROKEAHA.111.635755. Epub 2011 Nov 3.
Reference Type
BACKGROUND
Lindsberg PJ, Pekkola J, Strbian D, Sairanen T, Mattle HP, Schroth G. Time window for recanalization in basilar artery occlusion: Speculative synthesis. Neurology. 2015 Nov 17;85(20):1806-15. doi: 10.1212/WNL.0000000000002129.
Reference Type
BACKGROUND
Palaniswami M, Yan B. Mechanical Thrombectomy Is Now the Gold Standard for Acute Ischemic Stroke: Implications for Routine Clinical Practice. Interv Neurol. 2015 Oct;4(1-2):18-29. doi: 10.1159/000438774. Epub 2015 Sep 18.
Reference Type
BACKGROUND
Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, Johnston KC, Johnston SC, Khalessi AA, Kidwell CS, Meschia JF, Ovbiagele B, Yavagal DR; American Heart Association Stroke Council. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015 Oct;46(10):3020-35. doi: 10.1161/STR.0000000000000074. Epub 2015 Jun 29.
Reference Type
BACKGROUND
Chen CJ, Ding D, Starke RM, Mehndiratta P, Crowley RW, Liu KC, Southerland AM, Worrall BB. Endovascular vs medical management of acute ischemic stroke. Neurology. 2015 Dec 1;85(22):1980-90. doi: 10.1212/WNL.0000000000002176. Epub 2015 Nov 4.
Reference Type
BACKGROUND
Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey GJ, Stewart-Wynne EG, Rosen D, McNeil JJ, Bladin CF, Chambers BR, Herkes GK, Young D, Donnan GA. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis. 2005;20(1):12-7. doi: 10.1159/000086121. Epub 2005 May 30.
Reference Type
BACKGROUND
Yeung JT, Matouk CC, Bulsara KR, Sheth KN. Endovascular revascularization for basilar artery occlusion. Interv Neurol. 2015 Jan;3(1):31-40. doi: 10.1159/000368968.
Reference Type
BACKGROUND
Punal-Rioboo J, Atienza G, Blanco M. Safety and Efficacy of Mechanical Thrombectomy Using Stent Retrievers in the Endovascular Treatment of Acute Ischaemic Stroke: A Systematic Review. Interv Neurol. 2015 Jul;3(3-4):149-64. doi: 10.1159/000430474.
Reference Type
BACKGROUND
Akins PT, Amar AP, Pakbaz RS, Fields JD; SWIFT Investigators. Complications of endovascular treatment for acute stroke in the SWIFT trial with solitaire and Merci devices. AJNR Am J Neuroradiol. 2014 Mar;35(3):524-8. doi: 10.3174/ajnr.A3707. Epub 2013 Sep 12.
Reference Type
BACKGROUND
Hann S, Chalouhi N, Starke R, Gandhe A, Koltz M, Theofanis T, Jabbour P, Gonzalez LF, Rosenwasser R, Tjoumakaris S. Comparison of neurologic and radiographic outcomes with Solitaire versus Merci/Penumbra systems for acute stroke intervention. Biomed Res Int. 2013;2013:715170. doi: 10.1155/2013/715170. Epub 2013 Dec 30.
Reference Type
BACKGROUND
von Kummer R, Broderick JP, Campbell BC, Demchuk A, Goyal M, Hill MD, Treurniet KM, Majoie CB, Marquering HA, Mazya MV, San Roman L, Saver JL, Strbian D, Whiteley W, Hacke W. The Heidelberg Bleeding Classification: Classification of Bleeding Events After Ischemic Stroke and Reperfusion Therapy. Stroke. 2015 Oct;46(10):2981-6. doi: 10.1161/STROKEAHA.115.010049. Epub 2015 Sep 1. No abstract available.
Reference Type
BACKGROUND
Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007 Jan 27;369(9558):275-82. doi: 10.1016/S0140-6736(07)60149-4.
Reference Type
BACKGROUND
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998 Oct 17;352(9136):1245-51. doi: 10.1016/s0140-6736(98)08020-9.
Reference Type
BACKGROUND
Puetz V, Sylaja PN, Coutts SB, Hill MD, Dzialowski I, Mueller P, Becker U, Urban G, O'Reilly C, Barber PA, Sharma P, Goyal M, Gahn G, von Kummer R, Demchuk AM. Extent of hypoattenuation on CT angiography source images predicts functional outcome in patients with basilar artery occlusion. Stroke. 2008 Sep;39(9):2485-90. doi: 10.1161/STROKEAHA.107.511162. Epub 2008 Jul 10.
Reference Type
BACKGROUND
Tomsick T, Broderick J, Carrozella J, Khatri P, Hill M, Palesch Y, Khoury J; Interventional Management of Stroke II Investigators. Revascularization results in the Interventional Management of Stroke II trial. AJNR Am J Neuroradiol. 2008 Mar;29(3):582-7. doi: 10.3174/ajnr.A0843.
Reference Type
BACKGROUND
Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke. 2003 Aug;34(8):e109-37. doi: 10.1161/01.STR.0000082721.62796.09. Epub 2003 Jul 17.
Reference Type
BACKGROUND
Liu X, Dai Q, Ye R, Zi W, Liu Y, Wang H, Zhu W, Ma M, Yin Q, Li M, Fan X, Sun W, Han Y, Lv Q, Liu R, Yang D, Shi Z, Zheng D, Deng X, Wan Y, Wang Z, Geng Y, Chen X, Zhou Z, Liao G, Jin P, Liu Y, Liu X, Zhang M, Zhou F, Shi H, Zhang Y, Guo F, Yin C, Niu G, Zhang M, Cai X, Zhu Q, Chen Z, Liang Y, Li B, Lin M, Wang W, Xu H, Fu X, Liu W, Tian X, Gong Z, Shi H, Wang C, Lv P, Tao Z, Zhu L, Yang S, Hu W, Jiang P, Liebeskind DS, Pereira VM, Leung T, Yan B, Davis S, Xu G, Nogueira RG; BEST Trial Investigators. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial. Lancet Neurol. 2020 Feb;19(2):115-122. doi: 10.1016/S1474-4422(19)30395-3. Epub 2019 Dec 9.
Reference Type
BACKGROUND
Writing Group for the BASILAR Group; Zi W, Qiu Z, Wu D, Li F, Liu H, Liu W, Huang W, Shi Z, Bai Y, Liu Z, Wang L, Yang S, Pu J, Wen C, Wang S, Zhu Q, Chen W, Yin C, Lin M, Qi L, Zhong Y, Wang Z, Wu W, Chen H, Yao X, Xiong F, Zeng G, Zhou Z, Wu Z, Wan Y, Peng H, Li B, Hu X, Wen H, Zhong W, Wang L, Jin P, Guo F, Han J, Fu X, Ai Z, Tian X, Feng X, Sun B, Huang Z, Li W, Zhou P, Tu M, Sun X, Li H, He W, Qiu T, Yuan Z, Yue C, Yang J, Luo W, Gong Z, Shuai J, Nogueira RG, Yang Q. Assessment of Endovascular Treatment for Acute Basilar Artery Occlusion via a Nationwide Prospective Registry. JAMA Neurol. 2020 May 1;77(5):561-573. doi: 10.1001/jamaneurol.2020.0156.
Reference Type
BACKGROUND
Jovin TG, Li C, Wu L, Wu C, Chen J, Jiang C, Shi Z, Gao Z, Song C, Chen W, Peng Y, Yao C, Wei M, Li T, Wei L, Xiao G, Yang H, Ren M, Duan J, Liu X, Yang Q, Liu Y, Zhu Q, Shi W, Zhu Q, Li X, Guo Z, Yang Q, Hou C, Zhao W, Ma Q, Zhang Y, Jiao L, Zhang H, Liebeskind DS, Liang H, Jadhav AP, Wen C, Brown S, Zhu L, Ye H, Ribo M, Chang M, Song H, Chen J, Ji X; BAOCHE Investigators. Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion. N Engl J Med. 2022 Oct 13;387(15):1373-1384. doi: 10.1056/NEJMoa2207576.
Reference Type
DERIVED
Hankey GJ. Endovascular Therapy for Acute Basilar Artery Occlusion. Circulation. 2022 Jul 5;146(1):18-20. doi: 10.1161/CIRCULATIONAHA.122.060571. Epub 2022 Jul 5. No abstract available.
Reference Type
DERIVED
Li C, Wu C, Wu L, Zhao W, Chen J, Ren M, Yao C, Yan X, Dong C, Song H, Ma Q, Duan J, Zhang Y, Zhang H, Jiao L, Wang Y, Jovin TG, Ji X; BAOCHE Investigators. Basilar Artery Occlusion Chinese Endovascular Trial: Protocol for a prospective randomized controlled study. Int J Stroke. 2022 Jul;17(6):694-697. doi: 10.1177/17474930211040923. Epub 2021 Aug 28.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Xuanwu201601
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion
NCT05615038
ACTIVE_NOT_RECRUITING
NA
Effect of Balloon Angioplasty vs Stenting Following Residual Stenosis After Endovascular Treatment of Intracranial Atherosclerotic Acute Ischemic Stroke
NCT07026331
ACTIVE_NOT_RECRUITING
NA
Multi-dimensional Evaluation System for Recanalization of Symptomatic Non-acute Carotid Artery Occlusion
NCT04291430
UNKNOWN
Efficacy of Rescue Stenting/Angioplasty After Failed Thrombectomy for Acute Large Intracranial Vascular Occlusion
NCT07026344
ACTIVE_NOT_RECRUITING
NA
Carotid Revascularization Versus Best Medical Treatment for Asymptomatic Carotid Stenosis
NCT05623904
RECRUITING
NA
A Prospective Multicenter Registry Study on BASIS Technique for Endovascular Therapy of Acute Large Vessel Occlusion Strokes Due to Intracranial Atherosclerotic Disease
NCT06881420
RECRUITING
To Assess the Effectiveness and Safety of Catheter-based Focal Intracranial Hypothermia Combined with Endovascular Reperfusion Therapy for Patients with Acute Anterior Circulation Large Artery Occlusion
NCT06758609
RECRUITING
NA
Investigation and Study on the Status of Endovascular Therapy in Acute Ischemic Stroke Ischemic Stroke
NCT03909438
UNKNOWN
Endovascular Treatment Key Technique and Emergency Work Flow Improvement of Acute Ischemic Stroke
NCT03370939
COMPLETED
The MRI-based Evaluation of Safety and Efficacy of EVT and SMT: A Retrospective, Multicenter Study
NCT06236828
COMPLETED
Direct Intra-arterial Thrombectomy in Order to Revascularize AIS Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals
NCT03469206
COMPLETED
NA
Safety and Efficacy of Selective Intra-Arterial Cooling Infusion Combined With EVT in Acute Ischemic Stroke
NCT06485427
RECRUITING
NA
Trial of Rescue Endovascular Treatment for Progressive Acute Mild Ischemic Stroke With Basilar Artery Occlusion With Extended Time Window
NCT06843356
RECRUITING
NA
Endovascular treatmenT for Acute Ischemic Stroke in China
NCT04752735
COMPLETED
Endovascular Treatment for AIS in Chinese Municipal and County Hospitals： A "Real World" Study-ETERNITY Registry
NCT06078917
COMPLETED
Registry of Acute Ischemic Stroke With Large- or Medium-vessel Occlusion
NCT05779215
RECRUITING
REperfusion Therapy for Acute Ischemic STrOke Due to Large aRtEry Occlusion
NCT05311605
RECRUITING
A Randomized Trial Of Endovascular Treatment For Acute Posterior Large Vessel Occlusion
NCT04743076
SUSPENDED
NA
Evaluation of Endovascular Treatment in Acute Intracranial Distal Medium Vessel Occlusion Stroke
NCT06146790
RECRUITING
NA
Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion
NCT06383182
RECRUITING
Local Ischemic Postconditioning in Acute Ischemic Stroke
NCT06526429
COMPLETED
NA
Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke With Mild Symptoms
NCT04526756
COMPLETED
NA
Prospective Registry Study of Endovascular Treatment for Acute Ischemic Stroke Patients
NCT05988125
RECRUITING
Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion
NCT06221371
COMPLETED
PHASE3
Large Artery Occlusion Treated in Extended Time with Mechanical Thrombectomy Trial
NCT05326932
RECRUITING
NA